Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.60 |
| ▸ | PDE4A | P27815 | 14/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7278320 | 1.00 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL7270844 | 1.00 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL7278324 | 1.00 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL7288403 | 1.00 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL4637716 | 0.93 | ALDH1A1 (0.55) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL4637257 | 0.92 | ALDH1A1 (0.54) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL7373523 | 0.84 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL7367183 | 0.84 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL7364734 | 0.83 | ALDH1A1 (0.48) | PDE4BPDE4APDE4CPDE4DPDE3B | |
| SCHEMBL7364522 | 0.80 | PDE4B (0.67) | PDE4BPDE4APDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468991-B1 | Imides as PDE III, PDE IV and TNF inhibitors | CELGENE CORP (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060264477-A1 | Methods of using cyclic amides | MULLER GEORGE W | 2006-11-23 | — | — | US | disclosed |
| US-7081464-B2 | Topical compositions of cyclic amides as immunotherapeutic agents | CELGENE CORPORATION (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060003979-A1 | Topical compositions of cyclic amides as immunotherapeutic agents | CELGENE CORPORATION | 2006-01-05 | — | — | US | disclosed |
| US-20050096355-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2005-05-05 | — | — | US | disclosed |
| EP-1468991-A1 | Imides as PDE III, PDE IV and TNF inhibitors | CELGENE CORPORATION (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-0874819-B1 | IMIDES AS PDE III, PDE IV AND TNF INHIBITORS | CELGENE CORP (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030114516-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-06-19 | — | — | US | disclosed |
| EP-0672031-B1 | CATECHOL DIETHERS AS SELECTIVE PDE IV INHIBITORS | PFIZER (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6518281-B2 | Heterocyclic amides/imides as inhibitors of tumor necrosis factor alpha and nuclear factor kappa B and phosphodi-esterases III and IV; used to combat cachexia, endotoxic shock, retrovirus replication and asthma; antiinflammatory | CELGENE CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-0470805-B1 | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents | AMERICAN HOME PROD (US) | 1994-09-07 | — | — | EP | disclosed |
| WO-1994012461-A1 | CATECHOL DIETHERS AS SELECTIVE PDEIV INHIBITORS | PFIZER INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5294730-A | A-Amino-4-alkoxy-3-polycycloalkyloxybenzyl cyanide derivatives | PFIZER INC. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0247725-B1 | Calcium independent camp phosphodiestrerase inhibitor antidepressant | PFIZER (US) | 1994-03-02 | — | — | EP | disclosed |
| US-5196426-A | CALCIUM INDEPENDENT C AMP PHOSPHODIESTERASE INHIBITOR ANTIDEPRESSANT | PFIZER INC. (US) | 1993-03-23 | — | — | US | disclosed |
| US-5128358-A | Aryl substituted nitrogen heterocyclic antidepressants | PFIZER INC. (US) | 1992-07-07 | — | — | US | disclosed |
| US-5124455-A | Enzyme inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-23 | — | — | US | disclosed |
| EP-0470805-A1 | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-02-12 | — | — | EP | disclosed |
| EP-0247725-A2 | Calcium independent camp phosphodiestrerase inhibitor antidepressant | PFIZER INC. (US) | 1987-12-02 | — | — | EP | disclosed |
| WO-1987006576-A1 | CALCIUM INDEPENDENT CAMP PHOSPHODIESTERASE INHIBITOR ANTIDEPRESSANT | PFIZER INC. (US) | 1987-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096355-A1 | Novel immunotherapeutic agents | STING1, RNASE1, CGAS | PDE4B 15/4885PDE4A 8/4885PDE4C 12/4885 |
| US-20030114516-A1 | Novel immunotherapeutic agents | STING1, RNASE1, CGAS | PDE4B 13/4885PDE4A 7/4885PDE4C 8/4885 |
| US-20060003979-A1 | Topical compositions of cyclic amides as immunotherapeutic agents | TSLP, STING1, CGAS | PDE4B 21/4885PDE4A 8/4885PDE4C 6/4885 |
| US-20060264477-A1 | Methods of using cyclic amides | RNASE1, RNGTT, CGAS | PDE4B 10/4885PDE4A 5/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.